Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 12/28/17 → 07/30/21 |
Funding
- Boehringer Ingelheim Pharmaceutical: $45,107.70
IQVIA RDS: A Phase III Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10mg Compared to Placebo in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
- Skopicki, Hal (PI)
- Bloom, Michelle (CoPI)
- Borriello, Caitlin (CoPI)
- Pilato, Lauren (CoPI)
- Tallman, Mark (CoI)
Project: Research